Mission: To provide hope to underserved patient communities
• Science dedicated to patients
• Embrace open communication and debate
• Trust, respect, and accountability
• One ...
At GBT, we share a sense of urgency to help alleviate suffering that patients with orphan diseases like sickle cell disease (SCD) face. Currently, we are developing our initial product candidate, voxelotor, as an oral, once-daily therapy for SCD. We’re also expanding our pipeline in an effort to tackle other severe rare diseases.
Interested in advancing your career surrounded by great colleagues? Take a look at our open job opportunities!
We find more efficient ways to move from research to treating patients. Early on we jumped at the potential to harness promising, well-understood science to discover and develop the first pill to treat the root cause of SCD. We are developing our initial product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease, or SCD, and are currently enrolling patients in our pivotal trial program called the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study. In the United States, we have received Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations and in the European Union, we have Orphan Drug and PRIME designations – proof that regulatory agencies have identified SCD as a severe unmet medical need.
The imperative to finding better medicines for neglected patients is what drives us. Our goal is to make our SCD drug the preferred standard of care for an estimated 100,000 people with SCD in the US and more than seven million worldwide living with SCD. This is no small feat. No wonder our CEO, Dr. Ted Love, came out of retirement to lead our mission.
Our empathy, creativity and passion to make a difference for patients, compels us to pursue new approaches and do our best work.
I have been working at Global Blood Therapeutics as a contractor (Less than a year)
Was treated well during the recruitment and interview process, which moved along at a reasonable pace.
Staff sincerely believes in their mission and wants to make a difference in the lives of their under served patients.
Very exciting and important drug!
CEO is down to earth and very well liked.
Office space is pleasantly designed and building is situated in a beautiful setting near a waterside walking trail.
Some growing pains but that is to be expected.
I applied through an employee referral. The process took 2 weeks. I interviewed at Global Blood Therapeutics (South San Francisco, CA) in January 2018.
GBT was very efficient in setting up the phone interviews (with HR and Supervisor) as well as the on-site interview. I was grateful that it wasn't an 8-hour interview, which can be exhausting. It was "only" a 4-hour interview (lunch was brought in), with all interviewers getting a half-hour (which is more than enough time). Follow-up was immediate, and the salary and start date were settled quickly.
Coming over 40 miles from East Bay, I appreciated the non-commute-hours interview time, as well as the lunch. Also, good directions were given to the building/parking, as well as a PDF of the company benefits.
I first started in the industry in 1988. GBT's process is definitely the exception on all fronts, rather than the rule. And yes, i did get offered the position and I accepted, but everything started off on the right foot with the interview.
Let us know if we're missing any workplace or industry recognition –